These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: The effect of peak and current serum panel-reactive antibody on graft survival.
    Author: Premasathian N, Panorchan K, Vongwiwatana A, Pornpong C, Agadmeck S, Vejbaesya S.
    Journal: Transplant Proc; 2008 Sep; 40(7):2200-1. PubMed ID: 18790191.
    Abstract:
    BACKGROUND: Preformed antibodies against HLA antigens are known risk factors for early graft loss. Pretransplantation panel-reactive antibody (PRA) is often used to estimate the degree of sensitization. This study was conducted to determine the risk of early graft loss among subjects with a PRA cutoff value of 10%. OBJECTIVES: To evaluate the influence on 1-year graft survival of pretransplant recipient sensitization using 10% peak and current PRA cutoff values. METHODS: From January 1988 to July 2007, T-cell and B-cell PRA data were available for 247 (41%) and 241 (40%) patients, respectively. Medical records were reviewed for graft survival, current PRA value, and peak PRA value (both T and B cell). Complement-dependent cytotoxicity (CDC) is the only method of PRA identification in this study. We analyzed the correlation between PRA level and graft survival. RESULTS: Current T-cell PRA > 10% was significantly associated with poorer 1-year graft survival when compared with those with PRA < or = 10% in kidney transplantation from both donor sources: 48.6% versus 86.3% (P = .007) for living donor 94.7% versus 70.0% (P = .029) for deceased donor. Most of the graft losses in recipients with a high PRA occurred within the first 3 months posttransplantation. CONCLUSION: In our experience, current serum T-cell CDC PRA value > 10% was significantly associated with a decreased 1-year graft survival; interventions will be required to preserved graft function in these high-risk individuals.
    [Abstract] [Full Text] [Related] [New Search]